News Apogee buy delivers eczema trial win for AbbVie AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
News AbbVie climbs post-Allergan M&A peak with Apogee buy AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.
News Apogee rises as long-acting eczema drug heads for phase 3 Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.
News Apogee Therapeutics upsizes its IPO to $300m In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill
News Helus shares slide on psychedelic readout in depression Helus has revealed data from a phase 3 trial of HLP003 that showed evidence of efficacy in depression, although its shares fell on safety concerns.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.